Skip to main content
. 2019 Jul 14;9(7):165. doi: 10.3390/brainsci9070165

Figure 1.

Figure 1

Experimental design and time-course of treatment and analysis. Wild-type, vehicle, and DPSC-CM treated mSOD1G93A mice were designated for assessment at either (A) an early pre-symptomatic disease stage (PD35–47), (B) late pre-symptomatic (PD70–91) stage, or (C) from symptom onset (PD100–110) to end-stage (PD110–134). Upon sacrifice, histologic analysis of NMJ innervation of the gastrocnemius, MN survival in the lumbar spinal cord and survival outcomes were performed dependent on time period of treatment.